Reviewer's report

Title: Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature

Version: 1 Date: 8 February 2013

Reviewer: Kathryn Momary

Reviewer's report:

This case report detailing the drug-drug interaction between warfarin and rifampicin. The report details the the efforts to get a therapeutic INR after starting rifampicin and after rifampicin.

While the authors make it sound as though this is the first case of it's kind, that is not true. This interaction has been well described in other literature. While this case may have more information included compared to previous reports, the information contained here is not new.

Major Compulsory Revisions
-This report is clouded by the patients previously documented non-compliance. It is unclear if the patient was taking warfarin during the time of potential "resistance", therefore the report of the interaction is complicated.
-This report should include a much more extensive discussion of enzyme induction drug interactions. Specifically, the timing of such interactions.
-The review of warfarin metabolism is incomplete. Please state how each enantiomer is metabolized. This is especially important given the discussion of CYP3A4 with isoniazid.
-The authors mention several tools used to assess the causality of the drug interaction on the adverse event. Scores from these tools should be included in the manuscript.
-The authors make it sound as though warfarin is a p-gp substrate. I do not believe this is true. Please edit this an ensure that it is correct.

Minor Essential Revisions
- The first paragraph of the case presentation section is unclear. Please revise
- Table 1 and figure 1 are highly repetitive. I do not believe that table 1 is necessary.

Level of interest: An article of insufficient interest to warrant publication in a scientific/medical journal

Quality of written English: Acceptable
**Statistical review:** No, the manuscript does not need to be seen by a statistician.

**Declaration of competing interests:**

I declare that I have no competing interests